Hamish Anderson, Cecilia Verryt, Paula Keating, Thomas Saunders, Samuel Dalton, Barry D Hock, Liping Goddard, Kylie Drake, Anja Werno, John O'Donnell, Jeffrey R Stinson, Andrew L Snow, Kuang-Chih Hsiao
{"title":"A novel case of autosomal recessive CARD11 loss-of-function underlying impaired antiviral immunity and a review of literature.","authors":"Hamish Anderson, Cecilia Verryt, Paula Keating, Thomas Saunders, Samuel Dalton, Barry D Hock, Liping Goddard, Kylie Drake, Anja Werno, John O'Donnell, Jeffrey R Stinson, Andrew L Snow, Kuang-Chih Hsiao","doi":"10.1002/cti2.70066","DOIUrl":"10.1002/cti2.70066","url":null,"abstract":"<p><strong>Objectives: </strong>Germline <i>CARD11</i> variants lead to a spectrum of disease depending on the effect of signalling augmentation or impairment. Autosomal recessive (AR) CARD11 loss-of-function (LOF) is rare with only 12 cases reported to date.</p><p><strong>Methods: </strong>Clinical and immunological information was collated for a patient with a homozygous <i>CARD11</i> p.(Arg379Pro) variant.</p><p><strong>Results: </strong>The patient (P1, aged 5, female) has a history of developmental delay and growth failure, severe early-onset asthma, impaired clearance of naturally acquired viruses and probable susceptibility to live attenuated vaccines (LAV). Genetic testing revealed that P1 has a hypomorphic homozygous novel missense variant in the coiled-coil (CC) domain of CARD11, leading to LOF. She has combined immunodeficiency with significant T and B cell defects, and impaired nuclear factor kappa B (NF-κB) activity in lymphocytes.</p><p><strong>Conclusion: </strong>We expand the phenotypic spectrum of CARD11-opathies by describing a patient homozygous for a novel AR LOF <i>CARD11</i> variant, demonstrating susceptibility to Japanese encephalitis and varicella LAV and impaired clearance of multiple naturally acquired respiratory viral infections. Inborn errors of immunity affecting the CARD11-BCL10-MALT1 (CBM) complex should be considered in individuals with LAV vaccine susceptibility and recurrent or persistent viral infections.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 ","pages":"e70066"},"PeriodicalIF":3.4,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13148971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147866126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lachlan J Dobson, Barry D Hock, Ariana Ht Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan
{"title":"Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide.","authors":"Lachlan J Dobson, Barry D Hock, Ariana Ht Drabble, Liping Goddard, Judith L McKenzie, Sean A MacPherson, Alexander D McLellan","doi":"10.1002/cti2.70098","DOIUrl":"10.1002/cti2.70098","url":null,"abstract":"<p><strong>Objectives: </strong>The anti-PD-L1 antibody avelumab has demonstrated efficacy across multiple cancer types. Avelumab primarily blocks the PD-1/L1 immune checkpoint, while inducing antibody-dependent cellular cytotoxicity (ADCC) from CD16a<sup>+</sup> NK cells. However, subsets of patients possess lower-affinity CD16a allotypes that limit ADCC capacity of monoclonal antibodies. In this study, we modified the Fc domain of avelumab with characterised mutations to enhance ADCC across all CD16a allotypes.</p><p><strong>Methods: </strong>Comparisons between the wild-type avelumab and modified 'AveFc5M' were carried out to assess the impacts of introduced mutations on PD-L1 blockade, ADCC induction and complement-dependent cytotoxicity (CDC) induction. To assess ADCC, a range of PD-L1<sup>+</sup> target cells were coated with mab prior to incubation with effector cells, with both high- and low-affinity CD16a allotypes represented. Human serum was employed for assessing CDC.</p><p><strong>Results: </strong>Both antibodies exhibited equivalent PD-L1 blocking activity. Notably, the modified AveFc5M displayed significantly enhanced ADCC across diverse tumor cell-effector cell combinations. Fc mutations also conferred the ability to mediate complement-dependent cytotoxicity (CDC) against a PD-L1<sup>+</sup> lymphoma cell line. However, short term activation of NK cells or long-term expansion on artificial antigen presenting cells, led to upregulation of PD-L1 on NK cells. Addition of avelumab or AveFc5M to these NK cell populations induced a marked reduction in viable NK cells via ADCC-mediated fratricide.</p><p><strong>Conclusion: </strong>These findings demonstrate that Fc engineering of avelumab can substantially augment ADCC and CDC activity against PD-L1<sup>+</sup> tumors. However, the enhanced effector function of AveFc5M led to NK cell fratricide, potentially limiting NK cell-dominated anti-cancer responses.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 ","pages":"e70098"},"PeriodicalIF":3.4,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13144752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer R Habel, Thi H O Nguyen, Natasha de Alwis, E Kaitlynn Allen, Shihan Li, Morgan J Skinner, Jennifer A Juno, Stephen J Kent, Katherine Bond, Deborah A Williamson, Martha Lappas, Natalie J Hannan, Susan Walker, Jan Schroeder, Jeremy Chase Crawford, Paul G Thomas, Katherine Kedzierska, Louise C Rowntree
{"title":"High-dimensional multiomics reveals perturbations to IL-6/IL-6R axis and RUNX3 in CD4<sup>+</sup> T cells during third-trimester pregnancy.","authors":"Jennifer R Habel, Thi H O Nguyen, Natasha de Alwis, E Kaitlynn Allen, Shihan Li, Morgan J Skinner, Jennifer A Juno, Stephen J Kent, Katherine Bond, Deborah A Williamson, Martha Lappas, Natalie J Hannan, Susan Walker, Jan Schroeder, Jeremy Chase Crawford, Paul G Thomas, Katherine Kedzierska, Louise C Rowntree","doi":"10.1002/cti2.70096","DOIUrl":"10.1002/cti2.70096","url":null,"abstract":"<p><strong>Objectives: </strong>CD4<sup>+</sup> T cells play key roles in regulating immune responses during pregnancy; therefore, we aimed to understand the CD4<sup>+</sup> T-cell surface proteome and transcriptome during pregnancy.</p><p><strong>Methods: </strong>CD4<sup>+</sup> T cells were analysed in blood and decidua from term pregnancies (> 37 weeks) and non-pregnant blood. > 350 surface proteins were screened via flow cytometry, and transcriptomes were analysed using single-cell RNA sequencing with > 130 CITE-seq barcoded antibodies.</p><p><strong>Results: </strong>Surface protein screening identified changes to ILT4/CD85d, CD9, IFN-γ receptor β-chain, CX3CR1 and CCR5 in the pregnant blood and decidual CD4<sup>+</sup> T cells. CX3CR1 and CCR5 had the highest expression on the effector-memory T-cell (T<sub>EM</sub>) subset in the blood, with expression consistent across subsets in decidua. CD126/IL-6R was lower in pregnant blood and decidual CD4<sup>+</sup> T cells, while scRNAseq identified enrichment in the IL-6R signalling pathway in naive CD4<sup>+</sup> T cells in pregnant blood. Both sIL-6R and IL-6 concentrations were increased in plasma during pregnancy, suggesting perturbations to the IL-6/IL-6R signalling axis. Meanwhile, decidual CD4<sup>+</sup> T cells had increased expression of transcription factor RUNX3 in the CD69<sup>+</sup> tissue-resident-like subset.</p><p><strong>Conclusions: </strong>Our findings demonstrate altered molecular expression in CD4<sup>+</sup> T cells during pregnancy. This provides important mechanistic insight of their adaptation and regulation during placental development, which may drive placental dysfunction or pregnancy complications, including preeclampsia, fetal growth restriction and stillbirth. These new data may inform future studies that focus on determining the significance of differentially expressed immune features in pregnancy to identify potential targets for immune modulation to treat pregnancy complications and infections.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 ","pages":"e70096"},"PeriodicalIF":3.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13125720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}